IMPORTANT DRUG WARNING

SUBJECT: Serious risks of autoimmune conditions, infusion reactions, and malignancies with LEMTRADA® (alemtuzumab); FDA-Required REMS Program

IMPORTANT SAFETY NOTICE

Dear Healthcare Provider:

The purpose of this letter is to inform you of the approval of LEMTRADA® (alemtuzumab); a CD52-directed cytolytic monoclonal antibody for intravenous infusion indicated for the treatment of patients with relapsing forms of multiple sclerosis (MS). Because of its safety profile, the use of LEMTRADA should generally be reserved for patients who have had an inadequate response to two or more drugs indicated for the treatment of MS.

The LEMTRADA REMS Program was developed by Genzyme in collaboration with the FDA to ensure that the benefits of LEMTRADA outweigh the serious risks. Under the LEMTRADA REMS Program, only prescribers, pharmacies, healthcare facilities, and patients enrolled in the Program are able to prescribe, dispense, administer, and receive LEMTRADA.

SERIOUS RISKS OF LEMTRADA

AUTOIMMUNE CONDITIONS

- LEMTRADA causes serious, sometimes fatal, autoimmune conditions such as immune thrombocytopenia and anti-glomerular basement membrane disease. Monitor complete blood counts with differential, serum creatinine levels, and urinalysis with urine cell counts at periodic intervals for 48 months after the last dose of LEMTRADA.

INFUSION REACTIONS

- LEMTRADA causes serious and life threatening infusion reactions. LEMTRADA can only be administered in certified healthcare settings that have on-site access to equipment and personnel trained to manage infusion reactions (including anaphylaxis and cardiac and respiratory emergencies).

MALIGNANCIES

- LEMTRADA may cause an increased risk of malignancy including thyroid cancer, melanoma, and lymphoproliferative disorders. Perform baseline and yearly skin exams to monitor for signs of melanoma.
IMPORTANT SAFETY INFORMATION ON KNOWN RISKS

Treatment with LEMTRADA® (alemtuzumab) can result in the formation of autoantibodies and increase the risk of serious autoimmune mediated conditions, including ITP, other cytopenias, thyroid disorders and glomerular nephropathies, which may occur many years after treatment. In order to identify these risks, laboratory tests are required. Complete blood counts with differential, serum creatinine levels and urinalysis with urine cell counts should be obtained prior to initiation of treatment and at monthly intervals until 48 months after the last infusion with LEMTRADA. Thyroid function tests should be obtained prior to initiation of treatment and every 3 months until 48 months after the last infusion with LEMTRADA. Monitoring may need to continue past 48 months based on clinical findings of autoimmune conditions.

Most patients treated with LEMTRADA in controlled clinical trials in MS experienced infusion reactions during or after LEMTRADA administration. Some infusion reactions may be serious and life threatening. Serious reactions occurred in 3% of patients and included anaphylaxis in 2 patients (including anaphylactic shock), angioedema, bronchospasm, hypotension, chest pain, bradycardia, tachycardia (including atrial fibrillation), transient neurologic symptoms, hypertension, headache, pyrexia and rash. Premedicate patients with high dose corticosteroids (1000 mg methylprednisolone or equivalent) immediately prior to the LEMTRADA infusion and for the first 3 days of any treatment course. Observe patients for infusion reactions during and for at least 2 hours after each LEMTRADA infusion. Longer periods of observation may be required if clinically indicated.

LEMTRADA may cause an increased risk of malignancy including thyroid cancer, melanoma, and lymphoproliferative disorders. Baseline and yearly skin examinations should be performed in LEMTRADA patients to monitor for signs of melanoma. Caution should be exercised in initiating LEMTRADA therapy in patients with pre-existing or ongoing malignancies.

The LEMTRADA REMS Program Requirements:

> **Prescribers** must be enrolled in the LEMTRADA REMS Program to be able to prescribe LEMTRADA.

> **Pharmacies** must be enrolled in the LEMTRADA REMS Program to be able to dispense LEMTRADA.

> **Healthcare Facilities** must be enrolled in the LEMTRADA REMS Program to be able to dispense and administer LEMTRADA.

> **Patients** must be enrolled and authorized in the LEMTRADA REMS Program in order to receive LEMTRADA.
Reporting Adverse Events

It is important that you promptly report all suspected adverse events with the use of LEMTRADA. Please contact Genzyme Medical Information at 1-800-745-4447 (option 2) or the FDA at 1-800-FDA-1088 (1-800-332-1088) or www.fda.gov/medwatch.

This letter is not a comprehensive description of the risks associated with the use of LEMTRADA. Please see the enclosed Prescribing Information for a complete description of these risks.

If you have any questions about the LEMTRADA REMS Program, please call 1-855-676-6326 for more information or visit www.LemtradaREMS.com.

Sincerely,

(Name)
(Title)
Genzyme Corporation